About Recludix Pharma
Recludix Pharma is a company based in San Diego (United States) founded in 2020. Recludix Pharma has raised $60 million across 1 funding round from investors including Westlake BioPartners, NEA and Access Industries. The company has 33 employees as of December 31, 2022. Recludix Pharma offers products and services including STAT6 Program, STAT3 Program, and BTK Program. Recludix Pharma operates in a competitive market with competitors including Insitro, Helix, Certara, HotSpot Therapeutics and Benchling, among others.
- Headquarter San Diego, United States
- Employees 33 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Recludix Pharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$60 M (USD)
in 1 rounds
-
Latest Funding Round
$60 M (USD), Series A
Nov 15, 2021
-
Investors
Westlake BioPartners
& 2 more
-
Employee Count
33
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Recludix Pharma
Recludix Pharma offers a comprehensive portfolio of products and services, including STAT6 Program, STAT3 Program, and BTK Program.
Targets SH2 domains for treating inflammatory diseases.
Focuses on protein interactions in inflammatory conditions.
Develops therapies for inflammation via key protein pathways.
People of Recludix Pharma
Unlock access to complete
Funding Insights of Recludix Pharma
Recludix Pharma has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series A round of $60 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Recludix Pharma
Recludix Pharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Westlake BioPartners, NEA and Access Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Westlake BioPartners is engaged in biotech venture capital investment.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Investment and holding company controlled by Len Blavatnik
|
Locked | Locked | Locked |
Investor details for Recludix Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Recludix Pharma
Investment portfolio details for Recludix Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Recludix Pharma
Detailed financials for Recludix Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Recludix Pharma Comparisons
Peer comparison for Recludix Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Recludix Pharma
Recludix Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Helix, Certara, HotSpot Therapeutics and Benchling, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
|
| Locked | Locked | Locked |
Provider of a platform for in silico drug discovery and consulting services
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Cloud-based bioinformatics platform is offered for biotech research.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
Detailed competitors of Recludix Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Recludix Pharma
Complete news archive for Recludix Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recludix Pharma
Recludix Pharma was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Recludix Pharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Nancy Whiting is the current CEO of Recludix Pharma.
Recludix Pharma is a funded company, having raised a total of $60M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Recludix Pharma is 33.
Recludix Pharma was founded in 2020 and is based in San Diego, United States. An online platform is offered by the company for drug discovery and development within the biotechnology sector. Researchers are assisted through the platform in identifying and predicting potent sites on STAT 3 and STAT 6 proteins. These targets are linked to cancer and inflammatory conditions, including rheumatoid arthritis, asthma, and atopic dermatitis.
Recludix Pharma's top competitors include Insitro, Helix and HotSpot Therapeutics.
Recludix Pharma offers STAT6 Program, STAT3 Program, and BTK Program.
Recludix Pharma has 3 investors. Key investors include Westlake BioPartners, NEA, and Access Industries.